Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 5/20 | 0.64 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.64 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.64 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.64 |
| ▸ | GSR | P00390 | 2/20 | 0.56 |
| ▸ | GRM8 | O00222 | 1/20 | 0.56 |
| ▸ | GRM6 | O15303 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.56 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norvaline SCHEMBL17449755 | 1.00 | — | — | |
| Norvaline SCHEMBL840389 | 1.00 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| Norvaline SCHEMBL38405 | 1.00 | — | — | |
| Norvaline SCHEMBL197812 | 1.00 | — | — | |
| Norvaline SCHEMBL38404 | 1.00 | — | — | |
| Norvaline SCHEMBL21114359 | 1.00 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| Norvaline SCHEMBL28670644 | 0.97 | SLC1A2 (0.61) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| Norvaline SCHEMBL28394825 | 0.97 | — | — | |
| Norvaline SCHEMBL30692359 | 0.97 | — | — | |
| Norvaline SCHEMBL4155453 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034364-A1 | USE OF PEPTIDES FOR IMPARTING KOKUMI | AJINOMOTO CO., INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| EP-2415359-A1 | USE OF PEPTIDE FOR IMPARTING BODY TASTE | Ajinomoto Co., Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034364-A1 | USE OF PEPTIDES FOR IMPARTING KOKUMI | GIPR, GABRA6, GABRB1 | SLC1A2 325/4885SLC1A1 380/4885SLC1A3 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.